Phase IV (2016-20)

in page functions

From 2016-2020, a new five-year strategy approved by the Gavi Board in 2014, will guide the Vaccine Alliance’s mission

GAVI Alliance replenishment brochure

The Vaccine Alliance's second replenishment will finance immunisation programmes for the 2016-2020 strategic period.

The GAVI Alliance Board has approved a revised five-year strategy to continue to build sustainable programmes and deliver on its mission to save children’s lives and protect people’s health by increasing equitable use of vaccines in lower income countries

The revised five-year strategy (2016-2020), approved by the Gavi Board on 19 June 2014, builds on the current strategy and draws lessons from the previous 15 years. The strategy is designed to adapt to the changing environment in which the Vaccine Alliance and the countries it is supporting will operate.


The 2016-20 strategy has four goals, each supporting Gavi’s overall mission: “to save children’s lives and protect people’s health by increasing equitable use of vaccines in lower income countries.”

  1. Accelerate equitable uptake and coverage of vaccines.
  2. Increase effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systems.
  3. Improve sustainability of national immunisation programmes.
  4. Shape markets for vaccines and other immunisation products.


The strategic framework includes eight principles, intended to define the Vaccine Alliance’s characteristics, its business model and its aspirations: country-led, community-owned, globally engaged, catalytic and sustainable, integrated, innovative, collaborative and accountable.

Strategic enablers

The new framework also includes four ‘strategic enablers’. These are critical elements that the Vaccine Alliance, including countries, need to put in place to successfully achieve the four strategic goals.

The strategic enablers are: In-country Leadership Management & Coordination, Advocacy, Resource Mobilisation and Monitoring & Evaluation.

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

More facts...

close icon

modal window here